Clinic
The William W Backus Hospital
The William W Backus Hospital was paid $163.01M by Medicaid between Jan 2018 and Dec 2024, across 531 billing codes. Its largest line is 99285, emergency room visit (most serious) — 22% of everything it billed.
33Billing provider infoTHE WILLIAM W BACKUS HOSPITAL
NORWICH, CT 06360
NORWICH, CT 06360
33aNPI1467517235assigned 12/22/2006
33bProvider typeEmergency Care Clinic/Center
28Total paid$163.01M
24GClaims3,316,330
24DCodes billed531
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Care Clinic/Center providers in Connecticut
Rank by total paid#1 of 6
Median peer was paid$80.66M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 414,653 | $19.33M | |
| 2019 | 473,704 | $22.53M | |
| 2020 | 413,560 | $18.51M | |
| 2021 | 502,508 | $23.30M | |
| 2022 | 500,290 | $24.49M | |
| 2023 | 530,409 | $27.76M | |
| 2024incomplete | 481,206 | $27.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 119,380 | 105,131 | $35.84M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 172,814 | 155,542 | $29.37M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.7% | 117,137 | 106,825 | $15.84M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.4% | 50,059 | 40,641 | $7.14M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.0% | 80,124 | 51,482 | $4.85M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 109,853 | 33,188 | $4.82M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 19,496 | 17,396 | $3.47M |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 42,559 | 38,080 | $2.27M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 18,742 | 12,666 | $2.27M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 46,064 | 34,718 | $2.25M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 14,457 | 11,883 | $1.95M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 1,112 | 913 | $1.62M |
519 more codes
| 59025 | Fetal non-stress test | <1% | 10,450 | $1.61M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 10,039 | $1.60M |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 35,284 | $1.56M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,097 | $1.46M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12,922 | $1.41M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 7,152 | $1.40M |
| 97010 | <1% | 31,733 | $1.35M | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 9,619 | $1.18M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,859 | $1.14M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 18,050 | $1.14M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,946 | $1.10M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 17,186 | $1.08M |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 7,813 | $1.06M |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,744 | $1.05M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,811 | $1.00M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,690 | $938K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 10,942 | $903K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 7,526 | $793K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 7,956 | $766K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 5,792 | $742K |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 7,169 | $739K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,041 | $715K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,118 | $687K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 7,808 | $667K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 28,997 | $659K |
| 97161 | <1% | 12,711 | $647K | |
| 93975 | <1% | 3,312 | $644K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 1,631 | $631K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 1,155 | $627K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,974 | $597K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 4,230 | $584K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,764 | $583K |
| 52356 | <1% | 183 | $574K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,264 | $521K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 784 | $501K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,845 | $480K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 90 | $424K |
| 64483 | <1% | 2,324 | $420K | |
| 72141 | <1% | 2,358 | $415K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 8,791 | $395K |
| 47562 | <1% | 88 | $392K | |
| 77334 | <1% | 1,413 | $367K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,858 | $361K |
| 76770 | <1% | 4,951 | $355K | |
| 90837 | Psychotherapy session, about an hour | <1% | 5,675 | $354K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,099 | $353K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 709 | $340K |
| 93971 | <1% | 5,242 | $337K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 21,643 | $336K |
| 97014 | <1% | 6,923 | $326K | |
| 71250 | <1% | 6,605 | $324K | |
| 77386 | <1% | 1,543 | $318K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,727 | $313K |
| 77336 | <1% | 4,180 | $291K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 14,185 | $290K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 57,019 | $290K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 32,555 | $284K |
| 73221 | <1% | 1,721 | $284K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,516 | $284K |
| 77412 | <1% | 2,900 | $270K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,671 | $269K |
| 77066 | Tomosynthesis, mammo | <1% | 2,236 | $258K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 22,492 | $251K |
| 76641 | <1% | 2,916 | $243K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 52,285 | $237K |
| 72110 | <1% | 6,038 | $225K | |
| 97162 | <1% | 4,834 | $221K | |
| 76536 | <1% | 2,936 | $221K | |
| 70496 | <1% | 1,524 | $218K | |
| 97035 | <1% | 4,416 | $214K | |
| 93970 | <1% | 1,785 | $214K | |
| 74183 | <1% | 1,068 | $202K | |
| 70491 | <1% | 1,250 | $183K | |
| 76642 | <1% | 3,058 | $182K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,897 | $182K |
| 97165 | <1% | 3,067 | $177K | |
| 73564 | <1% | 7,429 | $173K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 302 | $171K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 98 | $164K |
| 96415 | <1% | 3,029 | $162K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,857 | $158K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 64 | $158K |
| 77300 | <1% | 901 | $156K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,742 | $143K |
| 72050 | <1% | 2,298 | $134K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,695 | $132K |
| 36430 | <1% | 794 | $127K | |
| 93308 | <1% | 852 | $113K | |
| 76801 | <1% | 1,192 | $113K | |
| 77080 | <1% | 1,207 | $112K | |
| 74178 | <1% | 560 | $111K | |
| 73700 | <1% | 1,847 | $108K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 626 | $107K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 3,288 | $107K |
| 10061 | <1% | 332 | $103K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,962 | $100K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,341 | $99K |
| 10060 | <1% | 629 | $99K | |
| 93017 | <1% | 3,918 | $97K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 247 | $96K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 3,663 | $92K |
| 52332 | <1% | 68 | $90K | |
| 0002A | <1% | 2,658 | $87K | |
| 0001A | <1% | 2,839 | $87K | |
| 74246 | <1% | 614 | $86K | |
| 86900 | <1% | 8,859 | $83K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,248 | $79K |
| 97012 | <1% | 1,397 | $77K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 736 | $77K |
| 70486 | <1% | 2,020 | $77K | |
| 72131 | <1% | 1,686 | $75K | |
| 73030 | <1% | 5,752 | $75K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,057 | $68K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 246 | $68K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 695 | $67K |
| 93798 | <1% | 1,047 | $65K | |
| 96367 | <1% | 2,021 | $65K | |
| 73630 | <1% | 6,999 | $64K | |
| 43235 | <1% | 112 | $60K | |
| 49083 | <1% | 173 | $60K | |
| 20610 | <1% | 739 | $59K | |
| 74018 | <1% | 3,974 | $59K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 3,201 | $58K |
| 71271 | <1% | 605 | $58K | |
| 15275 | <1% | 125 | $57K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 5,170 | $52K |
| 73130 | <1% | 5,246 | $51K | |
| 72040 | <1% | 1,864 | $50K | |
| 73610 | <1% | 5,825 | $48K | |
| 72070 | <1% | 1,465 | $46K | |
| 76813 | <1% | 491 | $45K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,206 | $42K |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 223 | $41K |
| 97116 | <1% | 3,151 | $41K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,235 | $41K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,236 | $41K |
| 73502 | <1% | 3,383 | $40K | |
| 95811 | <1% | 81 | $39K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,800 | $39K |
| 73110 | <1% | 3,915 | $35K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 158 | $30K |
| 76870 | <1% | 937 | $29K | |
| 96417 | <1% | 611 | $29K | |
| 76882 | <1% | 469 | $29K | |
| 93880 | <1% | 383 | $28K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 68 | $26K |
| 72100 | <1% | 1,613 | $25K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 531 | $22K |
| 77295 | <1% | 25 | $22K | |
| 36561 | <1% | 14 | $22K | |
| 74174 | <1% | 130 | $21K | |
| 78431 | <1% | 34 | $21K | |
| 19083 | <1% | 25 | $21K | |
| 93225 | <1% | 336 | $19K | |
| 94060 | <1% | 136 | $18K | |
| 77338 | <1% | 148 | $18K | |
| 73080 | <1% | 2,157 | $17K | |
| 73140 | <1% | 2,268 | $17K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 215 | $17K |
| 97166 | <1% | 321 | $16K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 986 | $16K |
| 92610 | <1% | 174 | $15K | |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 259 | $15K |
| 77301 | <1% | 37 | $15K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,686 | $15K |
| 77280 | <1% | 149 | $15K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 212 | $14K |
| 72158 | <1% | 72 | $14K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 122,279 | $14K |
| 99205 | Prolong outpt/office vis | <1% | 270 | $13K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 205 | $13K |
| 96402 | <1% | 630 | $12K | |
| 80053 | Comprehensive metabolic panel | <1% | 97,595 | $12K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 346 | $12K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 85 | $11K |
| 99243 | <1% | 316 | $11K | |
| 76970 | <1% | 118 | $10K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13,676 | $10K |
| 74240 | <1% | 94 | $10K | |
| 97163 | <1% | 250 | $10K | |
| 0004A | <1% | 267 | $10K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 318 | $9K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 447 | $9K |
| 77290 | <1% | 31 | $9K | |
| 99223 | Prolong inpt eval add15 m | <1% | 140 | $8K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,163 | $8K |
| 0064A | <1% | 218 | $8K | |
| 98968 | <1% | 241 | $8K | |
| 0031A | <1% | 220 | $7K | |
| 70498 | <1% | 1,353 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 796 | $7K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,504 | $7K |
| 96523 | <1% | 206 | $6K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 23 | $6K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 62 | $6K |
| 72197 | <1% | 15 | $6K | |
| 99241 | <1% | 241 | $6K | |
| 73590 | <1% | 1,414 | $6K | |
| 98967 | <1% | 242 | $6K | |
| 94726 | <1% | 215 | $6K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 91 | $6K |
| 72146 | <1% | 26 | $5K | |
| 97597 | <1% | 81 | $5K | |
| G0378 | Hospital observation service, per hour | <1% | 13,772 | $5K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 81 | $5K |
| 73560 | <1% | 570 | $5K | |
| 10005 | <1% | 14 | $5K | |
| 36591 | <1% | 303 | $5K | |
| 99255 | <1% | 80 | $5K | |
| 74220 | <1% | 58 | $4K | |
| 99236 | Prolong inpt eval add15 m | <1% | 31 | $4K |
| 12011 | <1% | 986 | $4K | |
| 29515 | <1% | 29 | $4K | |
| 0012A | <1% | 148 | $4K | |
| 0003A | <1% | 100 | $4K | |
| 0011A | <1% | 163 | $4K | |
| 12001 | <1% | 2,199 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $3K |
| 94618 | <1% | 83 | $3K | |
| 99254 | <1% | 44 | $3K | |
| 70544 | <1% | 17 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 24,014 | $3K |
| 73090 | <1% | 693 | $3K | |
| 74241 | <1% | 13 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 31,899 | $3K |
| 64484 | <1% | 413 | $3K | |
| 80061 | Lipid panel | <1% | 446 | $3K |
| 71101 | <1% | 146 | $3K | |
| 73562 | <1% | 241 | $3K | |
| 95251 | <1% | 306 | $2K | |
| 95806 | <1% | 24 | $2K | |
| 72192 | <1% | 62 | $2K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 98 | $2K |
| 0071A | <1% | 63 | $2K | |
| 74247 | <1% | 16 | $2K | |
| 71100 | <1% | 360 | $2K | |
| 0072A | <1% | 58 | $2K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 82 | $2K |
| 73200 | <1% | 25 | $2K | |
| 20552 | <1% | 12 | $2K | |
| 90674 | <1% | 131 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,517 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 79 | $2K |
| 86923 | <1% | 64 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,455 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 17 | $2K |
| 99220 | <1% | 18 | $2K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 12 | $2K |
| 72128 | <1% | 29 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,434 | $1K |
| 72170 | <1% | 240 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,655 | $1K |
| 88342 | <1% | 1,718 | $1K | |
| 86850 | <1% | 8,767 | $1K | |
| 92611 | <1% | 13 | $1K | |
| 85027 | <1% | 4,700 | $1K | |
| 0054A | <1% | 39 | $1K | |
| 83735 | <1% | 18,980 | $1K | |
| 74181 | <1% | 14 | $1K | |
| 99442 | <1% | 87 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,521 | $1K |
| 99253 | <1% | 46 | $1K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 15 | $1K |
| 99234 | <1% | 27 | $1K | |
| 90686 | <1% | 100 | $1K | |
| 12002 | <1% | 522 | $972.80 | |
| 87641 | <1% | 406 | $968.67 | |
| 74230 | <1% | 13 | $951.44 | |
| 76857 | <1% | 14 | $877.72 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,037 | $872.70 |
| 99443 | <1% | 55 | $872.19 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,117 | $859.35 |
| L3809 | Wrist hand finger orthosis, without joint(s), prefabricated, off-the-shelf, any type | <1% | 13 | $830.09 |
| 70490 | <1% | 14 | $801.09 | |
| 81025 | <1% | 24,280 | $798.15 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,668 | $775.44 |
| 84484 | <1% | 21,299 | $756.31 | |
| 83690 | <1% | 35,219 | $750.91 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,377 | $748.77 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 14,928 | $644.28 |
| 73552 | <1% | 38 | $630.54 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,416 | $614.44 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 15 | $594.72 |
| 29125 | <1% | 1,021 | $587.84 | |
| 81003 | <1% | 60,315 | $576.87 | |
| 93270 | <1% | 27 | $532.46 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,094 | $502.80 |
| 87400 | <1% | 6,623 | $495.21 | |
| 85610 | <1% | 38,163 | $486.32 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,427 | $481.34 |
| 96376 | <1% | 9,399 | $446.51 | |
| 90715 | <1% | 4,571 | $422.44 | |
| 73660 | <1% | 39 | $417.32 | |
| 73060 | <1% | 112 | $412.11 | |
| 82962 | <1% | 32,857 | $363.48 | |
| 83605 | <1% | 13,119 | $356.29 | |
| 83880 | <1% | 3,388 | $321.71 | |
| 82947 | <1% | 129 | $312.48 | |
| 88307 | <1% | 1,097 | $293.96 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,777 | $285.21 |
| 86901 | <1% | 8,864 | $282.50 | |
| 87081 | <1% | 6,804 | $272.68 | |
| 84439 | <1% | 275 | $272.12 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 236 | $265.40 |
| 87077 | <1% | 8,019 | $258.47 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 372 | $242.87 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,491 | $233.90 |
| 87040 | <1% | 14,019 | $230.57 | |
| 84703 | <1% | 10,800 | $215.93 | |
| 83550 | <1% | 670 | $203.40 | |
| 85379 | <1% | 10,185 | $193.66 | |
| 85730 | <1% | 3,097 | $180.59 | |
| 76937 | <1% | 2,212 | $180.16 | |
| 11045 | <1% | 65 | $177.92 | |
| 82728 | <1% | 119 | $173.79 | |
| 87186 | <1% | 5,776 | $172.34 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 33,381 | $168.28 |
| 88360 | <1% | 96 | $160.64 | |
| 84702 | <1% | 3,079 | $153.20 | |
| 83540 | <1% | 697 | $150.52 | |
| 86140 | <1% | 6,435 | $144.62 | |
| 99219 | <1% | 120 | $121.51 | |
| 82077 | <1% | 2,751 | $119.33 | |
| 73522 | <1% | 12 | $116.21 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 72,249 | $115.10 |
| 86780 | <1% | 13 | $113.76 | |
| 86618 | <1% | 4,087 | $96.58 | |
| 80076 | <1% | 853 | $93.47 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 34 | $90.09 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 776 | $86.72 |
| Q3014 | Telehealth originating site facility fee | <1% | 12 | $85.94 |
| 85652 | <1% | 5,007 | $80.10 | |
| 82803 | <1% | 1,070 | $77.73 | |
| 88304 | <1% | 1,946 | $73.36 | |
| 87070 | <1% | 3,862 | $69.26 | |
| 72202 | <1% | 13 | $58.93 | |
| 87205 | <1% | 5,551 | $52.35 | |
| 82570 | <1% | 385 | $49.40 | |
| 80179 | <1% | 445 | $49.32 | |
| 87088 | <1% | 505 | $47.06 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 633 | $43.65 |
| 87808 | <1% | 1,043 | $40.19 | |
| 84156 | <1% | 501 | $35.00 | |
| 87807 | <1% | 927 | $34.56 | |
| 84100 | <1% | 887 | $32.24 | |
| 90839 | <1% | 281 | $29.80 | |
| 82550 | <1% | 2,519 | $28.73 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 437 | $26.50 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 188 | $24.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,956 | $23.36 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 30,005 | $22.16 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 29,761 | $21.87 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,679 | $20.34 |
| 86308 | <1% | 904 | $19.99 | |
| 87484 | <1% | 251 | $19.34 | |
| J2704 | Injection, propofol, 10 mg | <1% | 23,692 | $18.08 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,694 | $17.53 |
| 80143 | <1% | 465 | $16.44 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 18,115 | $15.22 |
| 82607 | <1% | 36 | $14.39 | |
| 82746 | <1% | 16 | $14.04 | |
| 87184 | <1% | 537 | $13.71 | |
| 87015 | <1% | 1,233 | $12.47 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 25,645 | $12.43 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,164 | $11.88 |
| 80164 | <1% | 115 | $10.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,793 | $9.79 |
| 82565 | <1% | 270 | $9.78 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 22,811 | $9.49 |
| 87147 | <1% | 410 | $9.39 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,638 | $9.26 |
| 87075 | <1% | 840 | $9.04 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 108 | $9.03 |
| 85045 | <1% | 14 | $9.02 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,345 | $8.39 |
| 87207 | <1% | 657 | $7.86 | |
| J3490 | Unclassified drugs | <1% | 369,624 | $7.52 |
| 82010 | <1% | 56 | $7.21 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 7,466 | $7.10 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,863 | $6.50 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 480 | $5.96 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,362 | $5.86 |
| 83615 | <1% | 164 | $5.76 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 10,982 | $5.19 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 123 | $5.12 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 810 | $4.35 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16,058 | $3.90 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 7,319 | $3.89 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 699 | $3.57 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,432 | $2.32 |
| G0008 | Administration of influenza virus vaccine | <1% | 249 | $2.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14,081 | $1.57 |
| 84132 | <1% | 1,095 | $1.45 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 278 | $1.34 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,614 | $1.14 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 206 | $0.99 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 91 | $0.63 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 2,822 | $0.61 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 41 | $0.24 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 23,779 | $0.16 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,232 | $0.12 |
| 84520 | <1% | 138 | $0.09 | |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 15 | $0.08 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | <1% | 13 | $0.04 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 13 | $0.04 |
| 99152 | 0% | 2,152 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 1,630 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 244 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 3,850 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 366 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 333 | $0.00 |
| 91300 | 0% | 5,589 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 1,274 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 1,613 | $0.00 |
| 87469 | 0% | 92 | $0.00 | |
| 88173 | 0% | 667 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 1,100 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 2,627 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 374 | $0.00 |
| 85014 | 0% | 989 | $0.00 | |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | 0% | 113 | $0.00 |
| C1729 | Catheter, drainage | 0% | 664 | $0.00 |
| 84145 | 0% | 452 | $0.00 | |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 23 | $0.00 |
| 82375 | 0% | 15 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 1,565 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 76 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 85 | $0.00 |
| 93356 | 0% | 77 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 1,475 | $0.00 |
| 94729 | 0% | 214 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 228 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 47 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 14 | $0.00 |
| 88112 | 0% | 109 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 87 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 765 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 131 | $0.00 |
| 0055T | 0% | 55 | $0.00 | |
| 87102 | 0% | 29 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 350 | $0.00 |
| 93226 | 0% | 174 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 458 | $0.00 |
| 89051 | 0% | 199 | $0.00 | |
| 51702 | 0% | 53 | $0.00 | |
| 84550 | 0% | 68 | $0.00 | |
| 22853 | 0% | 16 | $0.00 | |
| 84295 | 0% | 107 | $0.00 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 69 | $0.00 |
| 82365 | 0% | 54 | $0.00 | |
| 20936 | 0% | 15 | $0.00 | |
| 20930 | 0% | 16 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 63 | $0.00 |
| 82140 | 0% | 15 | $0.00 | |
| 82374 | 0% | 106 | $0.00 | |
| 77012 | 0% | 13 | $0.00 | |
| 77002 | 0% | 12 | $0.00 | |
| 76942 | 0% | 15 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,752 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 5,387 | $0.00 |
| 86617 | 0% | 525 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 7,111 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 11,787 | $0.00 |
| 72020 | 0% | 73 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 1,197 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 892 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 1,546 | $0.00 |
| C1769 | Guide wire | 0% | 2,676 | $0.00 |
| 88341 | 0% | 808 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 5,618 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 1,156 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 11,934 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 6,659 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 205 | $0.00 |
| 88300 | 0% | 492 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 2,849 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 996 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 3,105 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 227 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 544 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 1,139 | $0.00 |
| 77001 | 0% | 248 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 273 | $0.00 |
| 96368 | 0% | 227 | $0.00 | |
| 85018 | 0% | 886 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 184 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 942 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 322 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 170 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 2,062 | $0.00 |
| 87486 | 0% | 63 | $0.00 | |
| 87468 | 0% | 250 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 632 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 359 | $0.00 |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 0% | 33 | $0.00 |
| 82435 | 0% | 106 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 624 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 110 | $0.00 |
| 91305 | 0% | 44 | $0.00 | |
| 74420 | 0% | 185 | $0.00 | |
| 91301 | 0% | 350 | $0.00 | |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | 0% | 127 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 67 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 120 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 27 | $0.00 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 26 | $0.00 |
| 87206 | 0% | 39 | $0.00 | |
| 87581 | 0% | 63 | $0.00 | |
| 91303 | 0% | 218 | $0.00 | |
| 87507 | 0% | 42 | $0.00 | |
| 91307 | 0% | 121 | $0.00 | |
| 91306 | 0% | 217 | $0.00 | |
| 0352U | 0% | 33 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 69 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 65 | $0.00 |
| 80177 | 0% | 16 | $0.00 | |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 22 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMASTROIANNI, ANTHONY (REGIONAL VP OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| The William W Backus Hospital | Norwich, CT | $2.28M |
| William W Backus Hospital | Norwich, CT | $455K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.